StockWatch
·

SK Minerals & Additives Ltd Q2 FY27 Results

SKMQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze#Cost led
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue74.4415.5%32.3%
Total Income74.7715.4%32.1%
Expenditure69.4716.5%30.9%
PBT5.302.6%44.6%
Net Profit3.782.0%46.2%
OPM10.12%0.55pp4.03pp
NPM5.05%0.66pp1.32pp
EPS3.112.6%60.1%
View full financials

Chemicals-sector lens on revenue/EBITDA growth shows core revenue roughly flat YoY while PAT fell ~30% as operating and net margins compressed on sharply higher finance and employee costs, with management's promised margin-improvement from manufacturing ramp-up not yet visible.

Q2 FY-2027 RESULTS · SKM

SK Minerals Q2 FY27 standalone PAT falls 30% YoY to ₹3.78 Cr as margins compress

PAT -29.63% YoY · revenue -1.69% · margins compressing

12 Nov 2026 · 3 min read
Revenue

₹74.44 Cr

-1.69% YoY

PAT (standalone)

₹3.78 Cr

-29.63% YoY

Net margin

5.05%

-1.3pp YoY

EPS

₹3.11

SK Minerals & Additives' standalone Q2 FY27 (quarter ended September 30, 2026) print is a year-on-year decline despite a sequential bounce: revenue slipped 1.7% YoY to ₹74.44 Cr (₹75.72 Cr in Q2 FY26) and PAT fell 29.6% YoY to ₹3.78 Cr (₹5.37 Cr), with basic EPS at ₹3.11 against ₹5.96 a year ago. That is a sharp reversal from the 131% YoY PAT growth the company had posted just one quarter earlier in Q1 FY27. The +15.5% sequential revenue recovery from Q1's ₹64.45 Cr should not be read as momentum — PAT grew only 2.0% QoQ to ₹3.78 Cr and margins slipped versus Q1 as well, so the quarter is weak on both the YoY and QoQ cuts. There is no formal sell-side coverage or published consensus for this BSE SME-platform microcap — a search turned up none — so no beat/miss call versus street can be made; vsStreet is unknown.

The scoreboard

Q2 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹74.44 Cr+15.5%-32.3%
Expenses₹69.47 Cr+16.5%-30.9%
PAT₹3.78 Cr+2.04%-29.63%
Net margin5.05%-0.7pp-1.3pp
EPS₹3.11+2.6%-60.1%

The margin story explains most of the shortfall. Net margin compressed to 5.05% from 7.07% a year ago, and operating margin to 10.12% from 11.56%, as total expenses rose to 92.9% of total revenue from 90.4%. Finance costs jumped 56% YoY to ₹2.17 Cr (₹1.39 Cr) as short-term borrowings grew to ₹111.71 Cr from ₹83.75 Cr at FY26-end, and employee costs rose 73% YoY to ₹2.59 Cr (₹1.50 Cr) as the company builds out headcount ahead of its manufacturing ramp-up. This runs counter to the margin-improvement guidance management gave on the Q4 FY26 concall (May 2026), where it said margins would improve "as its in-house manufacturing, particularly for unique products like halogen-free flame retardants, scales up" — on this quarter's numbers that improvement has not shown up yet; if anything margins moved the other way, so guidance reads missed for now, pending the capacity ramp.

₹
360.96399.94438.93477.91516.89434.708-1009-0109-2410-1911-1111-12Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹434.7, up 3.5% over the past month of trading.

₹ Cr
02.625.247.867.02Q2 FY25rev ₹110 Cr7.02Q2 FY26rev ₹110 Cr3.7Q1 FY27rev ₹64 Cr3.78Q2 FY27rev ₹74 Cr
Quarterly standalone PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

Basic EPS of ₹3.11 versus diluted EPS of ₹2.64, the gap reflecting dilution from the newly issued convertible warrants

What management guided (4 FY-2026 call)
Management expects continued strong momentum in FY27, driven by increased manufacturing contribution from new polymer additives and capacity expansion. While raw material price volatility impacted recent margins, the company anticipates improved margins as its in-house manufacturing, particularly for unique products li

— This quarter: missed

Context for the quarter: the company drew down ₹54.52 Cr (25% of the ₹218.07 Cr preferential warrant issue allotted in August 2026) toward the previously-guided 18,000-tonne capacity expansion, though only ₹39.21 lakh of the ₹5.05 Cr capex object disclosed in the IPO prospectus has actually been utilised as of September 30, 2026 — the expansion is funded but barely deployed. The quarter also saw the company's first-ever export sales, ₹8.24 Cr (11% of revenue), against zero exports in both the year-ago and preceding quarters — an early but new diversification datapoint consistent with management's stated focus on strategic sourcing and new product development. No separate management press release or commentary accompanied this filing beyond the regulatory board-outcome letter, so there is no additional company framing to reconcile against the numbers. Half-year FY27 cumulative revenue is still up 26.4% YoY to ₹138.89 Cr and PAT up 6.6% YoY to ₹7.48 Cr, but that reflects Q1's unusually strong base-effect comparison rather than sustained momentum carrying into Q2.

  • W1

    18,000-tonne capacity expansion (guided 12-18 months from the Aug-2026 warrant allotment) — only ₹39.21 lakh of the ₹5.05 Cr capex object utilised as of Sep-30-2026; watch utilisation pace

  • W2

    Margin inflection — management guided NPM/OPM improvement as manufacturing scales, but OPM fell to 10.12% (from 11.56% YoY) and NPM to 5.05% (from 7.07% YoY) this quarter; next print needs to show the turn

  • W3

    Export sales of ₹8.24 Cr appeared for the first time this quarter (11% of revenue, zero a year/quarter ago) — watch whether this becomes a recurring stream

Only a standalone statement exists (no consolidated section). Figures converted from ₹ Lakhs; no exceptional items in either period. Our DB's 'year-ago quarter' record (revenue ₹109.89 Cr, PAT ₹7.02 Cr, EPS ₹7.79) actually matches this filing's H1 FY26 half-year column, not the Q2 FY26 standalone quarter (₹75.72 Cr revenue, ₹5.37 Cr PAT, EPS ₹5.96, per this filing's own comparative) — YoY here uses the filing's quarterly comparative, not the DB record. Diluted EPS (₹2.64) is below basic (₹3.11) due to dilution from warrants allotted this quarter.

Informational and educational content only. Not investment advice.